Radical cystectomy vs trimodality therapy for muscle-invasive bladder cancer: further extensive evaluation needed - Authors' reply

Affiliations

¹ Division of Urology, Department of Surgery, Mount Sinai Hospital, Sinai Health System, University of Toronto, Toronto, ON M5T 3L9, Canada; Division of Urology, Department of Surgical Oncology, University Health Network, Toronto, ON, Canada. Electronic address: alexandre.zlotta@sinaihealth.ca.
² Department of Biostatistics, University Health Network, Toronto, ON, Canada.
³ Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Comment

Alexandre R Zlotta et al. Lancet Oncol. 2023 Aug.

. 2023 Aug;24(8):e325-e326.

doi: 10.1016/S1470-2045(23)00322-4.

¹ Division of Urology, Department of Surgery, Mount Sinai Hospital, Sinai Health System, University of Toronto, Toronto, ON M5T 3L9, Canada; Division of Urology, Department of Surgical Oncology, University Health Network, Toronto, ON, Canada. Electronic address: alexandre.zlotta@sinaihealth.ca.
² Department of Biostatistics, University Health Network, Toronto, ON, Canada.
³ Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

No abstract available

Conflict of interest statement

Declarations of interest remain the same as in the original Article.

Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis.
Zlotta AR, Ballas LK, Niemierko A, Lajkosz K, Kuk C, Miranda G, Drumm M, Mari A, Thio E, Fleshner NE, Kulkarni GS, Jewett MAS, Bristow RG, Catton C, Berlin A, Sridhar SS, Schuckman A, Feldman AS, Wszolek M, Dahl DM, Lee RJ, Saylor PJ, Michaelson MD, Miyamoto DT, Zietman A, Shipley W, Chung P, Daneshmand S, Efstathiou JA. Zlotta AR, et al. Lancet Oncol. 2023 Jun;24(6):669-681. doi: 10.1016/S1470-2045(23)00170-5. Epub 2023 May 12. Lancet Oncol. 2023. PMID: 37187202
Radical cystectomy vs trimodality therapy for muscle-invasive bladder cancer: further extensive evaluation needed.
Jena R, Issa R, Perry M. Jena R, et al. Lancet Oncol. 2023 Aug;24(8):e324. doi: 10.1016/S1470-2045(23)00321-2. Lancet Oncol. 2023. PMID: 37541275 No abstract available.